Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (Nasdaq: AMRS) serves as a hub for tracking developments at the forefront of sustainable biotechnology. This resource aggregates official updates from the synthetic biology leader currently undergoing strategic restructuring while maintaining its commitment to transforming consumer markets through bioscience innovations.
Investors and industry observers will find comprehensive coverage of financial updates, leadership changes, and operational milestones. The collection includes press releases detailing AMRS's Chapter 11 restructuring progress, R&D advancements through its Lab-to-Market™ platform, and partnerships supporting its shift toward core biotechnology competencies.
Key content focuses on operational restructuring efforts, sustainability initiatives, and technology licensing agreements. Users can monitor updates about the company's consumer brand divestitures, cost optimization strategies, and ongoing supply chain relationships with global manufacturers.
Bookmark this page for streamlined access to verified AMRS communications, including regulatory filings and strategic partnership announcements. Check back regularly for the latest developments as Amyris positions itself for long-term stability in sustainable ingredient markets.
Amyris, Inc. (Nasdaq: AMRS) announced participation in three investor conferences from May 23 to May 25, 2022. The events include the Morgan Stanley Sustainable Futures Conference, Cowen 6th Annual Future of the Consumer Conference, and UBS Global Healthcare Conference. These conferences will enhance Amyris's visibility in the sustainable consumption sector and showcase its Lab-to-Market™ technology platform, which leverages machine learning and robotics to innovate rapidly. Live webcasts of the presentations will be available on the company's Investor Relations website.
Amyris, Inc. (Nasdaq: AMRS) announced its participation in two upcoming investor conferences. The first is the Morgan Stanley Sustainable Futures Conference on May 23 at 2:00 PM ET (virtual), followed by the UBS Global Healthcare Conference on May 25 at 11:30 AM ET (in-person). Live webcasts of these presentations will be accessible through the company's Investor Relations section. Amyris leverages its Lab-to-Market technology platform to facilitate the transition to sustainable consumption.
Amyris, Inc. (Nasdaq: AMRS) reported Q1 2022 financial results, achieving a record consumer revenue of $34.6 million, a 121% increase from Q1 2021. Core revenue reached $57.7 million, up 75% year-over-year, despite total revenue declining 67% due to the absence of a one-off strategic transaction from the previous year. The company plans to launch new brands and expects consumer revenue to grow over 150% in 2022. Cash at the end of the quarter was $288 million, a substantial increase from $144 million a year prior.
Amyris, Inc. (Nasdaq: AMRS) will announce its financial results for Q1 2022 on May 10, 2022, before market opening. A conference call is scheduled for 6:00 a.m. PT (9:00 a.m. ET) where CEO John Melo and CFO Han Kieftenbeld will discuss the results and business updates. Amyris utilizes its Lab-to-Market™ platform to transition the Clean Health & Beauty and Flavors & Fragrances markets to sustainable ingredients, reaching over 300 million consumers with products in more than 20,000 brand offerings.
Amyris, a synthetic biotechnology leader, hosted a successful investor event on April 11, 2022, following its Nasdaq Opening Bell ceremony. Key highlights included presentations on its sustainable consumer brands powered by its Lab-to-Market™ technology platform and an update on its precision fermentation plant in Barra Bonita, Brazil, which recently began commissioning operations. The event also featured a consumer panel discussing trends in clean beauty and the benefits of Amyris' proprietary technology. CEO John Melo emphasized the company’s commitment to sustainable products and their increasing consumer appeal.
Amyris, Inc. (Nasdaq: AMRS) has begun commissioning its new fermentation plant in Barra Bonita, Brazil, a strategic investment poised to enhance its biotechnology manufacturing capabilities. The facility, located next to the Raizen sugar mill, will utilize sugar cane as a primary feedstock. The plant features a vertical fermentation process and five mini-factories for producing over 13 bio-fermented products. This development aims to address increasing consumer demand for bio-based products and strengthen Amyris's position in the biotechnology sector.
Amyris, Inc. (Nasdaq: AMRS), a leader in synthetic biotechnology, will participate in a fireside chat at the Jefferies Virtual Synthetic Biology Week on March 23, 2022, at 2:00 pm ET. This event aims to showcase Amyris's innovative Lab-to-Market™ technology, which accelerates the transition to sustainable consumption. Investors can access a live webcast and replay on the company’s Investor Relations page. Amyris is known for its sustainable ingredients used across over 20,000 products, impacting over 300 million consumers globally.
Amyris, Inc. (Nasdaq: AMRS) has completed the acquisition of MenoLabs, LLC, a company that focuses on women's health, particularly addressing menopause symptoms. MenoLabs offers research-backed, all-natural treatments, including its flagship product, MenoFit, and a subscription model for online sales. The acquisition supports Amyris's strategy in the wellness sector, leveraging MenoLabs' recurring revenue and innovative product line. With this move, Amyris aims to enhance its portfolio in sustainable health solutions, tapping into the growing demand for menopause-related products.
Amyris, a synthetic biotechnology company, reported strong financial results for Q4 and full-year 2021. Consumer revenue hit a record $32.2 million, a remarkable 86% increase year-over-year, driven by brands like Biossance and new launches such as JVN and Rose Inc. Technology access revenue also rose 54% to $32.6 million. Despite a 19% decline in total revenue due to one-off strategic transactions, core revenue grew 68% to $64.8 million. The company anticipates doubling total revenue in 2022, supported by operational improvements and a strong consumer brand strategy.
Amyris, a leading synthetic biotechnology company, announced its participation in a fireside chat at the 42nd Annual Cowen Health Care Conference on March 7, 2022, at 1:30 pm ET. The event will focus on the company's Lab-to-Market™ technology platform, which drives sustainable consumption in the Clean Health & Beauty and Flavors & Fragrances sectors. A live webcast of the presentation and a replay will be available on the company's Investor Relations website. Amyris products reach over 300 million consumers and are featured in more than 20,000 items worldwide.
